Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.92 | N/A | +15.72% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.92 | N/A | +15.72% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
Eli Lilly's strong EPS performance, exceeding expectations, led to a positive stock reaction, with shares rising 2.1%. The company did not disclose revenue figures or future guidance, leaving investors to focus on the EPS beat as a sign of operational strength. Overall, the results indicate a solid quarter for the company, but uncertainty remains without further guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 23, 2012